BR112022021640A2 - Usos e formulações de canabinoides - Google Patents
Usos e formulações de canabinoidesInfo
- Publication number
- BR112022021640A2 BR112022021640A2 BR112022021640A BR112022021640A BR112022021640A2 BR 112022021640 A2 BR112022021640 A2 BR 112022021640A2 BR 112022021640 A BR112022021640 A BR 112022021640A BR 112022021640 A BR112022021640 A BR 112022021640A BR 112022021640 A2 BR112022021640 A2 BR 112022021640A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- cannabinoids
- covid
- patients suffering
- cannabidiol
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title abstract 5
- 239000003557 cannabinoid Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 229940065144 cannabinoids Drugs 0.000 title abstract 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 3
- 229950011318 cannabidiol Drugs 0.000 abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
USOS E FORMULAÇÕES DE CANABINOIDES. A presente invenção refere-se a usos e formulações de canabinoides, em particular de canabidiol. Os canabinoides, em particular o canabidiol, são utilizados para o tratamento de pacientes que sofrem de COVID-19, uma doença provocada pelo coronavírus SARS-Cov-2. As formulações são especialmente para administração oral de canabinoides, em particular de canabidiol. Estas formulações são úteis para o tratamento de pacientes que sofrem de COVID-19.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2020/063086 WO2021228365A1 (en) | 2020-05-11 | 2020-05-11 | Uses and formulations of cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022021640A2 true BR112022021640A2 (pt) | 2022-12-13 |
Family
ID=70861443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022021640A BR112022021640A2 (pt) | 2020-05-11 | 2020-05-11 | Usos e formulações de canabinoides |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230181484A1 (pt) |
EP (1) | EP4149445A1 (pt) |
JP (1) | JP2023534361A (pt) |
CN (1) | CN115884759A (pt) |
AR (1) | AR122059A1 (pt) |
AU (1) | AU2020447636A1 (pt) |
BR (1) | BR112022021640A2 (pt) |
CA (1) | CA3181940A1 (pt) |
IL (1) | IL298060A (pt) |
MX (1) | MX2022014199A (pt) |
WO (1) | WO2021228365A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021247269A1 (en) * | 2020-03-29 | 2022-12-01 | Akseera Pharma Corp. | Interaction of SARS-CoV-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat Covid-19. |
CA3179022A1 (en) * | 2020-07-18 | 2021-10-07 | Akseera Pharma Corp. | Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19 |
CN111686095A (zh) * | 2020-07-24 | 2020-09-22 | 中国人民解放军军事科学院军事医学研究院 | 大麻二酚在制备治疗冠状病毒感染的药物中的用途 |
WO2023225554A1 (en) * | 2022-05-17 | 2023-11-23 | The Regents Of The University Of California | Cannabinoids and il-15 activate nk cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
WO2015065179A1 (en) | 2013-10-29 | 2015-05-07 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
GB2542797A (en) * | 2015-09-29 | 2017-04-05 | Gw Pharma Ltd | Use of cannabinoids in the treatment of inflammatory skin diseases |
CN108697803A (zh) * | 2015-10-29 | 2018-10-23 | 索卢贝斯特有限公司 | 透粘膜给药的药物组合物 |
WO2018035030A1 (en) | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | Time release fat-soluble actives |
WO2019155337A1 (en) * | 2018-02-06 | 2019-08-15 | Scicann Therapeutics Inc. | Compositions comprising a cannabinoid and punicalagin and methods of use thereof |
CA3108214A1 (en) * | 2018-07-18 | 2020-01-23 | Glatt Gmbh | Extended release formulations of cannabinoids |
-
2020
- 2020-05-11 JP JP2022568566A patent/JP2023534361A/ja active Pending
- 2020-05-11 CN CN202080100824.XA patent/CN115884759A/zh active Pending
- 2020-05-11 IL IL298060A patent/IL298060A/en unknown
- 2020-05-11 WO PCT/EP2020/063086 patent/WO2021228365A1/en unknown
- 2020-05-11 MX MX2022014199A patent/MX2022014199A/es unknown
- 2020-05-11 AU AU2020447636A patent/AU2020447636A1/en active Pending
- 2020-05-11 EP EP20728681.6A patent/EP4149445A1/en active Pending
- 2020-05-11 BR BR112022021640A patent/BR112022021640A2/pt unknown
- 2020-05-11 CA CA3181940A patent/CA3181940A1/en active Pending
- 2020-05-11 US US17/923,731 patent/US20230181484A1/en active Pending
-
2021
- 2021-05-11 AR ARP210101284A patent/AR122059A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021228365A1 (en) | 2021-11-18 |
MX2022014199A (es) | 2022-12-06 |
EP4149445A1 (en) | 2023-03-22 |
AU2020447636A1 (en) | 2022-12-08 |
CN115884759A (zh) | 2023-03-31 |
IL298060A (en) | 2023-01-01 |
JP2023534361A (ja) | 2023-08-09 |
US20230181484A1 (en) | 2023-06-15 |
AR122059A1 (es) | 2022-08-10 |
CA3181940A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
BR112022001413A2 (pt) | Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet | |
BR112019001794A2 (pt) | composição de cannabis | |
GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
BR0114927A (pt) | Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição | |
BRPI0519803A2 (pt) | métodos para purificar trans-(-)-delta9-tetraidrocanabinol e trans-(+)-delta9-tetraidrocanabinol | |
BR112021022139A2 (pt) | Preparação de canabidiol, e, método para tratar um paciente que sofre de espasmos epilépticos | |
BR112019001852A2 (pt) | composição de cannabis | |
BR112017027836A2 (pt) | método para o tratamento de inflamação usando compostos naturais e/ou dieta | |
BR112017007774A2 (pt) | Um ou uma combinação dos fitocanabinoides canabidiol (cbd); canabidivarina (cbdv); e tetra- hidrocanabivarina (thcv), combinação dos fitocanabinoides, formulação farmacêutica, e, método para tratamento de um indivíduo que sofre de distrofia muscular de duchenne (dmd). | |
BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
CL2022002564A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
BR112023019967A2 (pt) | Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina | |
WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
CO2023000130A2 (es) | Composición y método para el tratamiento del dolor crónico | |
BR112023000747A2 (pt) | Composições para o tratamento de obesidade | |
BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
BRPI0607976A2 (pt) | composição farmacêutica e uso de uma composição | |
BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
BR112017025189A2 (pt) | composição e usos da mesma | |
BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
BR112015023368A2 (pt) | método de tratamento de deficiência de vitamina b12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |